Sign in

You're signed outSign in or to get full access.

Adam Snyder

Research Analyst at Sandtree Capital

Adam Snyder is an Analyst at Sandtree Capital, specializing in fundamental equity research with coverage of key companies in the technology and consumer sectors. Known for his detailed analysis of firms such as Apple, Amazon, and Microsoft, Snyder has consistently delivered actionable insights, with a track record that includes a top-quartile success rate and above-average portfolio returns as recognized by performance platforms. Snyder began his financial career over a decade ago, holding research roles at established investment firms before joining Sandtree Capital in 2021. He maintains professional credentials including FINRA registration, multiple securities licenses, and recognition as a CFA charterholder.

Adam Snyder's questions to IGC Pharma (IGC) leadership

Question · Q2 2026

Adam Snyder asked if the newly passed government funding bill impacting the hemp industry would have any effect on IGC Pharma's phase two CALMA trial.

Answer

Ram Mukunda, CEO of IGC Pharma, assured that no impact is expected on the CALMA trial. He explained that IGC 81 is an investigational new drug under rigorous regulatory oversight by the FDA and Health Canada, distinct from the consumer hemp market targeted by the bill. Furthermore, the legislation is scheduled to take effect in approximately one year, and the company anticipates completing the trial well before this effective date, thus insulating the trial's completion and primary data readout from any impending regulatory changes.

Ask follow-up questions

Fintool

Fintool can predict IGC Pharma logo IGC's earnings beat/miss a week before the call

Question · Q2 2026

Adam Snyder from Sandtree Capital asked about the potential impact of the recently passed government funding bill affecting the hemp industry on IGC Pharma's ongoing phase two CALMA trial.

Answer

Ram Mukunda, CEO of IGC Pharma, clarified that the company does not expect any impact on the CALMA trial. He explained that IGC 81 is an investigational new drug under rigorous regulatory oversight, distinct from the consumer hemp market targeted by the bill. Mukunda also noted that the legislation takes effect in approximately one year, and the CALMA trial is expected to be completed well before then, insulating it from impending regulatory changes.

Ask follow-up questions

Fintool

Fintool can write a report on IGC Pharma logo IGC's next earnings in your company's style and formatting